Article
Medicine, General & Internal
Sander F. Garrelfs, Yaacov Frishberg, Sally A. Hulton, Michael J. Koren, William D. O'Riordan, Pierre Cochat, Georges Deschenes, Hadas Shasha-Lavsky, Jeffrey M. Saland, William G. van't Hoff, Daniel G. Fuster, Daniella Magen, Shabbir H. Moochhala, Gesa Schalk, Eva Simkova, Jaap W. Groothoff, David J. Sas, Kristin A. Meliambro, Jiandong Lu, Marianne T. Sweetser, Pushkal P. Garg, Akshay K. Vaishnaw, John M. Gansner, Tracy L. McGregor, John C. Lieske
Summary: Primary hyperoxaluria type 1 is a rare genetic disease caused by hepatic overproduction of oxalate, leading to kidney stones, nephrocalcinosis, kidney failure, and systemic oxalosis. This trial tested the efficacy of lumasiran, an RNAi therapeutic agent, in reducing hepatic oxalate production. The results showed that lumasiran significantly reduced urinary oxalate excretion, alleviating the cause of kidney failure in PH1 patients.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Urology & Nephrology
Sander F. Garrelfs, Dewi van Harskamp, Hessel Peters-Sengers, Chris H. P. van den Akker, Ronald J. A. Wanders, Frits A. Wijburg, Johannes B. van Goudoever, Jaap W. Groothoff, Henk Schierbeek, Michiel J. S. Oosterveld
Summary: The study revealed that stable isotope infusion can quantify oxalate kinetics parameters, which can be used to evaluate therapeutic efficacy, investigate pyridoxine responsiveness, and further explore glyoxylate metabolism in humans.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2021)
Editorial Material
Urology & Nephrology
Justine Bacchetta, Kyle D. Wood
Summary: This article reviews the significant progress in understanding and treating genetic primary hyperoxaluria, including the impact of gene mutations, medical therapy, and novel treatments. It also discusses the different perspectives of adult and pediatric nephrologists, as well as the challenges faced by physicians and patients in developing countries.
CLINICAL KIDNEY JOURNAL
(2022)
Review
Urology & Nephrology
Harjivan Kohli, Michael P. Kurtz
Summary: This review summarizes the surgical approaches for treating primary hyperoxaluria (PH) and highlights the specific considerations for each method, including shockwave lithotripsy, percutaneous nephrostolithotomy, and ureteroscopy. The potential risks and benefits of each treatment approach are evaluated, with a focus on the importance of considering the patient's renal function status when developing a treatment plan for PH stones.
CLINICAL KIDNEY JOURNAL
(2022)
Article
Transplantation
Prince Singh, Jason K. Viehman, Ramila A. Mehta, Andrea G. Cogal, Linda Hasadsri, Devin Oglesbee, Julie B. Olson, Barbara M. Seide, David J. Sas, Peter C. Harris, John C. Lieske, Dawn S. Milliner
Summary: Primary hyperoxaluria type 3 (PH3) is characterized by symptoms at a younger age compared to PH1 and PH2, with lower urine oxalate excretion and higher urine calcium levels. Stone events are similar across age groups and PH types, with a lower risk of kidney failure in PH3 patients compared to PH1 and PH2 by age 40. Long-term follow-up studies of larger cohorts are needed to further understand the PH3 phenotype.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2022)
Article
Zoology
Rui Zheng, De-Xin Zhang, Yan-Jiao Shao, Xiao-Liang Fang, Lei Yang, Ya-Nan Huo, Da-Li Li, Hong-Quan Geng
Summary: This study demonstrated the potential of the Cpf1 CRISPR system to simultaneously target multiple genes and alleviate the pathogenic phenotype in primary hyperoxaluria type I (PH1). Targeting the Hao1 and Ldha genes resulted in decreased oxalate levels and improved disease pathology in PH1 rats, providing a proof-of-concept for multiplex genome editing-based gene therapy.
ZOOLOGICAL RESEARCH
(2023)
Review
Urology & Nephrology
Justine Bacchetta, John C. Lieske
Summary: Primary hyperoxaluria type 1 (PH1) is a rare and severe genetic disease, with traditional supportive treatments. However, new therapies based on RNA interference have brought new treatment prospects for the disease.
CLINICAL KIDNEY JOURNAL
(2022)
Review
Urology & Nephrology
Sonia Fargue, Cecile Acquaviva Bourdain
Summary: Primary hyperoxaluria type 1 (PH1) is a rare genetic disease caused by a deficiency in a liver-specific enzyme, leading to excessive oxalate synthesis and resulting in kidney stone disease and other severe complications.
CLINICAL KIDNEY JOURNAL
(2022)
Article
Medicine, General & Internal
Rachel D'Amico, Djhenne Dalmacy, Jenifer A. Akinduro, Madison Hyer, Stephen Thung, Shengyi Mao, Naleef Fareed, Seuli Bose-Brill
Summary: Gestational diabetes (GD) affects pregnancy and increases the risk of type 2 diabetes. The study aimed to explore how often individuals with GD access primary care and type 2 diabetes screening.
Review
Urology & Nephrology
Asheeta Gupta, Michael J. G. Somers, Michelle A. Baum
Summary: Supportive treatment for PH1 includes high fluid intake and crystallization inhibitors. Pyridoxine and RNA interference agents can reduce urinary oxalate. Kidney dysfunction often leads to end-stage kidney disease and systemic oxalate deposition. Hemodialysis and liver transplantation are important treatments.
CLINICAL KIDNEY JOURNAL
(2022)
Article
Genetics & Heredity
Aiysha Abid, Ali Raza, Tahir Aziz, Shagufta Khaliq
Summary: This study describes new cases of HOGA1 gene pathogenic variants and provides a comprehensive overview of PH type III associated variants. The majority of reported variants are missense variants that predict a loss of function mechanism. Founder mutations have been identified in various populations, but there is no significant genotype-phenotype correlation. Nephrocalcinosis is rare in patients with disease-associated variants, and most patients experience urolithiasis in early life.
Editorial Material
Surgery
Somashekara Hosaagrahara Ramakrishna, Akhila Hassan, Mohan Babu Kasala, Karnan Perumal, Chaitra Venkategowda, Selvakumar Malleeswaran, Muthukumar Periasamy, Muruganandham Kaliyaperumal, Rajanikanth Patcha, Joy Varghese, Mettu Srinivas Reddy
Summary: We report a case of a 12-year-old boy with primary hyperoxaluria type 2 who underwent a combined liver and kidney transplant, resulting in normalization of plasma oxalate and creatinine levels immediately and after 18 months.
AMERICAN JOURNAL OF TRANSPLANTATION
(2023)
Article
Urology & Nephrology
Prince Singh, Candace F. Granberg, Peter C. Harris, John C. Lieske, Jeffrey H. Licht, Andrew Weiss, Dawn S. Milliner
Summary: Primary hyperoxaluria (PH) is a genetic disorder that results in increased hepatic production of oxalate. PH type 3 (PH3) is the most recently identified subtype and can lead to kidney failure. Family history of the disease and marked hyperoxaluria can suggest the presence of PH3. Treatment options include hydration and medication.
AMERICAN JOURNAL OF KIDNEY DISEASES
(2022)
Article
Urology & Nephrology
Michelle A. Baum, Craig Langman, Pierre Cochat, John C. Lieske, Shabbir H. Moochhala, Shuzo Hamamoto, Hiroyuki Satoh, Chebl Mourani, Gema Ariceta, Armando Torres, Martin Wolley, Vladimir Belostotsky, Thomas A. Forbes, Jaap Groothoff, Wesley Hayes, Burkhard Toenshoff, Tatsuya Takayama, Ralf Rosskamp, Kerry Russell, Jing Zhou, Aniruddha Amrite, Bernd Hoppe
Summary: Nedosiran, an investigational RNA interference agent, demonstrated significant reductions in urinary oxalate levels in participants with primary hyperoxaluria (PH), particularly in the PH1 subgroup. Nedosiran also showed a sustained reduction in plasma oxalate and was generally safe and well tolerated. These findings indicate the potential of nedosiran as a treatment option for PH.
KIDNEY INTERNATIONAL
(2023)
Article
Gastroenterology & Hepatology
Pierre Nahon, Christophe Aube, Lucile Moga, Julia Chalaye, Boris Guiu, Alain Luciani, Agnes Rode, Maxime Ronot, Olivier Seror, Michael Soussan, Olivier Sutter, Marc Bourliere, Christophe Bureau, Victor de Ledinghen, Nathalie Ganne-Carrie
Summary: Hepatocellular carcinoma (HCC) is the most common malignant liver tumor that develops on a background of cirrhosis, and histological confirmation is not mandatory in many cases due to typical radiological patterns described by contrast-enhanced imaging. Liver biopsy may be essential in atypical presentations or to exclude other rare malignant tumors developed in the absence of cirrhosis.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY
(2022)
Article
Microbiology
Frieder Fuchs, Alexander Maximilian Aldejohann, Ada Marie Hoffmann, Grit Walther, Oliver Kurzai, Axel G. Hamprecht
Summary: The antifungal activity of nitroxoline was assessed in yeasts from urinary tract infections, and the results showed that nitroxoline is highly effective against various Candida species, regardless of resistance to other antifungal agents.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Article
Pharmacology & Pharmacy
Ada Marie Hoffmann, Martina Wolke, Jan Rybniker, Georg Plum, Frieder Fuchs
Summary: Nitroxoline demonstrates excellent in vitro activity against Mycobacterium tuberculosis complex, including multidrug-resistant isolates. Further studies should evaluate the potential role of nitroxoline in the treatment of tuberculosis in the era of drug resistance.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Infectious Diseases
Ada Marie Hoffmann, Martina Wolke, Jan Rybniker, Georg Plum, Frieder Fuchs
Summary: This study assessed the in vitro activity of the old antimicrobial nitroxoline against drug-resistant Mycobacterium abscessus complex (MYABS) isolates. The results showed that nitroxoline has promising antimicrobial activity against drug-resistant MYABS isolates.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2023)